Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 20,854 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,694 · Balance 18,848 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 20,598 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,591 · Balance 22,189 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 3,069 · Balance 25,258 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,404 · Balance 20,854 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 7,800 · Balance 7,800 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,206 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 3,069 · Balance 9,206 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,182 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,591 · Balance 3,182 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,750 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 1,750 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,694 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 31,150 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 31,150 · Balance 31,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2021 Filed Apr 28, 2021 21:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 23,725 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001179110-21-004651 · edgar.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,725 Underlying: Class A Common Shares · 23,725 shares Expires 2031-04-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 26, 2021. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003733 · edgar.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,158 Underlying: Class A Common Shares · 2,158 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003733 · edgar.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,019 Underlying: Class A Common Shares · 3,019 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003619 · edgar.xml · derivative · entry 2 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488 Underlying: Class A Common Shares · 3,488 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 20,925 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001179110-21-003619 · edgar.xml · derivative · entry 1 Ragosa Mark · CIK 0001835458 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,925 Underlying: Class A Common Shares · 20,925 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 4,404 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000198 · edgar.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 4,404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. F2 · derivative.expiration_date: The RSU will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,297 | $17.67 | $22,917.99 |
DisclosureSEC source: 0001179110-21-000198 · edgar.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,107 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,404 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-000198 · edgar.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.